Leerink and Cowen already purchased the shares at $19.505 which is at a discount to the public. As for EPZM, they raised the money they needed. In hindsight, this seems like it was a smart move.
On March 17, 2015, Epizyme, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC and Cowen and Company, LLC, as representatives of the several underwriters (collectively, the "Underwriters"), relating to an underwritten public offering of 6,000,000 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"). All of the Shares are being sold by the Company. The offering price to the public is $20.75 per share, and the Underwriters have agreed to purchase the Shares from the Company pursuant to the Underwriting Agreement at a price of $19.505 per share. Under the terms of the Underwriting Agreement, the Company granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 900,000 shares of Common Stock at the same price per share as the Shares.